2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N14619
    Rhodirubin B 64502-82-5
    Rhodirubin B has a strong anti-Gram-positive bacteria effect, and also has an effect on Mycobacterium. Rhodirubin B can also prolong the survival time of mice inoculated with leukemia L-1210.
    Rhodirubin B
  • HY-N14623
    Paulomycin B 81988-76-3
    Paulomycin B has anti-Gram-positive bacteria effect, and it has inhibitory effect on Staphylococcus aureus resistant to penicillin, Streptomycin, Neomycin and Macrolide antibiotics.
    Paulomycin B
  • HY-N14625
    Harziphilone 183239-75-0
    Harziphilone has weak anti-Gram-positive bacterial activity and anti-tumor effect, it can inhibit lymphoblastic leukemia L1210 and leukemia P388 with IC50 of 0.26 μg/mL. Harziphilone inhibits the binding of viral particle regulatory (REV) proteins to [33P] labeled viral particle regulatory effector element (RRE) RNA, IC50 is 2.0 μM.
    Harziphilone
  • HY-N14626
    Pelagiomicin C 173485-82-0
    Pelagiomicin C has the activity against Gram-positive bacteria and Gram-negative bacteria.
    Pelagiomicin C
  • HY-N14627
    Liposidomycin A 99751-55-0
    Liposidomycin A has antibacterial effect, but the antibacterial activity is weak. Liposidomycin A has strong inhibition of mycobacteria (MIC is 0.16 μg/mL). Liposidomycin A has the function of inhibiting glycopeptide biosynthesis, and can inhibit the glycopeptide biosynthesis of E.coli with an IC50 of 0.03 μg/mL.
    Liposidomycin A
  • HY-N14628
    Liposidomycin B 99751-53-8
    Liposidomycin B has antibacterial effect, but the antibacterial activity is weak. Liposidomycin B has strong inhibition of mycobacteria (MIC is 0.16 μg/mL). Liposidomycin B has the function of inhibiting glycopeptide biosynthesis, and can inhibit the glycopeptide biosynthesis of E.coli with an IC50 of 0.03 μg/mL.
    Liposidomycin B
  • HY-N14629
    Liposidomycin C 99751-54-9
    Liposidomycin C has antibacterial effect, but the antibacterial activity is weak. Liposidomycin C has strong inhibition of mycobacteria (MIC is 0.16 μg/mL). Liposidomycin C has the function of inhibiting glycopeptide biosynthesis, and can inhibit the glycopeptide biosynthesis of E.coli with an IC50 of 0.03 μg/mL.
    Liposidomycin C
  • HY-N14630
    Lividomycin B 37636-51-4
    Lividomycin B is an aminoglycoside antibiotic. Lividomycin B has a broad-spectrum effect against bacteria and Mycobacterium, and has no cross-resistance with /i>Streptomyces and penicillium, and has protective effect on mice infected with S. aureus and Pseudomonas aeruginosa.
    Lividomycin B
  • HY-N14635
    Paeciloquinone A 162797-33-3
    Paeciloquinone A can inhibit EGFR protein tyrosine kinase. Paeciloquinone A inhibits the V-abl protein tyrosine kinase with an IC50 of 0.59 μM.
    Paeciloquinone A
  • HY-N14636
    Paeciloquinone B 162797-34-4
    Paeciloquinone B can inhibit the EGFR protein tyrosine kinase.
    Paeciloquinone B
  • HY-N14637
    Paeciloquinone C 92439-42-4
    Paeciloquinone C can inhibit the EGFR protein tyrosine kinase. Paeciloquinone C inhibits the V-abl protein tyrosine Kinase with an IC50 of 0.56 μM.
    Paeciloquinone C
  • HY-N14638
    Paeciloquinone D 162797-35-5
    Paeciloquinone D can inhibit the EGFR protein tyrosine kinase.
    Paeciloquinone D
  • HY-N14639
    Paeciloquinone E 162797-36-6
    Paeciloquinone E can inhibit the EGFR protein tyrosine kinase.
    Paeciloquinone E
  • HY-N14640
    Paeciloquinone F 162797-37-7
    Paeciloquinone F can inhibit the EGFR protein tyrosine kinase.
    Paeciloquinone F
  • HY-N14644
    Hazimycin 5 84894-71-3
    Hazimycin 5 has weak activity against Gram-negative bacteria, yeast and skin fungi.
    Hazimycin 5
  • HY-N14650
    Hazimycin 6 84885-57-4
    Hazimycin 6 has weak activity against Gram-negative bacteria, yeast and skin fungi.
    Hazimycin 6
  • HY-N14651
    Glucosylquestiomycin 218150-62-0
    Glucosylquestiomycin has anti-Gram positive bacteria, negative bacteria and yeast activity.
    Glucosylquestiomycin
  • HY-N14652
    Glycocinnasperimicin D 99260-73-8
    Glycocinnasperimicin D is a glycoside cinnamyl imide histamine antibiotic. Glycocinnasperimicin D has the activity of anti-Gram positive bacteria and negative bacteria. Glycocinnasperimicin D inhibits leukemia L1210 cell with an IC50 of 2.0 μg/mL.
    Glycocinnasperimicin D
  • HY-N14653
    Glysperin A 78213-56-6
    Glysperin A has anti-Gram positive bacteria and negative bacteria (including aminoglycoside antibiotic resistant bacteria) activity.
    Glysperin A
  • HY-N14654
    Glysperin B 78213-55-5
    Glysperin B has anti-Gram positive bacteria and negative bacteria (including aminoglycoside antibiotic resistant bacteria) activity.
    Glysperin B
Cat. No. Product Name / Synonyms Application Reactivity